During Friday’s Afternoon trade, Shares of Isle of Capri Casinos(NASDAQ:ISLE), gain 0.21% to $18.95.
Isle of Capri Casinos, Inc. (ISLE) stated financial results for the first quarter of fiscal year 2016 ended July 26, 2015.
Fiscal 2016 First Quarter Highlights
- Net revenues raised 4.2% to $246.9 million year over year.
- Adjusted EBITDA raised 15.9% to $51.1 million year over year.
- Adjusted EBITDA margin raised to 20.7%, up 210 bps year over year.
Merged Results
Virginia McDowell, president and chief executive officer, commented: “We grew Adjusted EBITDA for the sixth successive quarter, and this quarter marks our fourth successive quarter with a double-digit, year-over-year enhance in Adjusted EBITDA.
Isle of Capri Casinos, Inc., together with its auxiliaries, develops, owns, and operates branded gaming facilities and related dining, lodging, and entertainment facilities in the United States. It owns or operates 15 gaming and entertainment facilities under the Isle and Lady Luck brand names in Colorado, Florida, Iowa, Louisiana, Mississippi, Missouri, and Pennsylvania.
Shares of Zogenix, Inc.(NASDAQ:ZGNX), inclined 0.33% to $19.69, during its Afternoon trading session.
Zogenix, Inc. (ZGNX) declared that at the annual general meeting of shareholders held earlier recently, shareholders voted to approve a proposal authorizing the board of directors of the Company to amend the Company’s certificate of incorporation to effect a reverse stock split of Zogenix’s outstanding common shares at an exchange ratio of 1-for-8, and a change in the number of authorized shares of common stock to 50,000,000 shares. Zogenix’s board of directors had formerly directed that the proposal be presented to the shareholders for approval and has subsequently determined that the reverse stock split will take effect on July 1, 2015. Starting with the opening of trading on July 1, 2015, the Company’s common stock will trade on a split-adjusted basis.
Zogenix, Inc., a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its marketed product comprises Zohydro ER, an extended-release formulation of hydrocodone for the treatment of severe chronic pain. The company also develops ZX008, a low-dose fenfluramine for the treatment of Dravet syndrome; and Relday, an injectable formulation of risperidone that is in Phase Ib clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older.
Regeneron Pharmaceuticals Inc(NASDAQ:REGN), during its Friday’s Afternoon trading session decreased -1.02% to $503.34.
Regeneron Pharmaceuticals, Inc. ( REGN) and Sanofi declared that the Phase 3 ODYSSEY JAPAN trial of the investigational therapy Praluent® (alirocumab) Injection met its primary endpoint. At week 24, patients in the Praluent group practiced an average 64 percent greater reduction from baseline in their bad cholesterol, known as low-density lipoprotein cholesterol (LDL-C), when added to current standard of care counting statins, contrast to standard of care alone (p less than 0.0001). Patients were started on the lower dose of 75 mg, with the option to adjust their dose to 150 mg if they had not achieved their LDL-C aim (as defined by the Japan Atherosclerosis Society guidelines) at week 8. At week 24, 97 percent of patients in the Praluent group reached their LDL-C treatment aim, contrast to 10 percent for placebo (p less than 0.0001). Ninety-nine percent of patients treated with Praluent remained on the lower dose; two patients required adjustment to the higher dose.
The trial involved 216 Japanese patients with hypercholesterolemia at high cardiovascular (CV) risk and/or with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH). Results were presented recently for the first time at the Annual Scientific Meeting of the Japan Atherosclerosis Society (JAS) in Sendai, Japan. Praluent is an investigational fully human monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).
Finally, HMS Holdings Corp (NASDAQ:HMSY), decreased -0.40%, to $9.60.
HMS Holdings Corp. (HMSY) declared that Jeff Sherman, CFO, will be presenting at the Wells Fargo Securities 2015 Healthcare Conference at 7:35am CT / 8:35am ET on September 10, 2015 at The Hyatt Regency Hotel in Boston, MA. A link to the audiocast and supporting materials will be accessible on the Company’s website at http://investor.hms.com/events.cfm.
HMS Holdings Corp., through its auxiliaries, provides healthcare insurance benefit cost containment services in the United States. The company’s coordination of benefits services provide cost avoidance services that offer validated insurance coverage information, which is used by government-sponsored payers to coordinate benefits for incoming claims; payment integrity services to identify improper payments on a pre-payment and post-payment basis, identify and recover overpayments, detect and prevent fraud and abuse, and identify process improvements; and eligibility verification services comprising asset and income verification, premium assistance, dependent eligibility audits, and other verification solutions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
